Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy
The aim of this study was to investigate the potential of progesterone receptor (PgR) as a biomarker for differentiating estrogen receptor (ER)-positive patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy (NCT) with different prognoses. A total of 327 consecutiv...
Main Authors: | , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Impact Journals LLC
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627243/ |